Shopping Cart

Fueling Scientific Discovery through Technological Breakthroughs


The transformative potential that lies in data collection and interpretation is being harnessed by industries and businesses globally – and the field of scientific research is no exception.

Flow cytometry is a powerful analytical tool used for identifying and quantifying cellular characteristics on a cell-by-cell basis up to tens of thousands of cells per second. This technology is used in research and clinical studies with various biomedical and therapeutic applications such as investigating the role of the body's immune system in fighting cancer, diagnosing leukemia and lymphoma, and detecting minimal residual disease in organ transplant patients. Flow cytometry has many advantages over traditional microscopy since it enables the analysis of a greater number of cells in a fraction of the time.

The power of gaining deep biological insights with powerful research tools such as a flow cytometer is accelerating the pace of discoveries that can be transferred to the clinic and drive improved patient outcomes. In fact, rapidly growing areas of research will drive the flow cytometry analyzer market to grow to more than $1 billion dollars by 2020.

While the benefits offered by flow cytometry are well known throughout the scientific community, adoption has lagged due its cost-prohibitive, workflow-intensive nature. Flow cytometry, once the domain of the most well-funded scientific research labs, is finding its way into a growing number of labs around the globe – thanks to companies like Cytek Biosciences.

Cytek Biosciences is addressing the lack of access to this advanced research tool by leveraging their breakthrough technologies to create new flow cytometry systems. These best-in-class, easy-to-use systems meet scientists' needs at appropriate price points, enabling them to derive rich, biological insights without breaking the bank. The company's latest product line, the Cytek Aurora, incorporates spectral technology to bring flow cytometry to the next level, enabling high multiplexing capability and excellent resolution of dim populations.

According to Cytek's CEO Dr. Wenbin Jiang, "With our technology, we are empowering scientists to obtain deeper insights from every single sample.

This ability to obtain more data from one sample accelerates the pace of discovery and can translate to the clinic, leading to improved patient monitoring and treatment for various diseases."

By offering affordability and capabilities that go beyond pricier flow cytometry systems, Cytek has made a distinct impression on the scientific community. In fact, its Cytek Aurora systems have been sold into four continents, with more on the immediate horizon.

When asked what sets Cytek apart from others in the flow cytometry space, Dr. Jiang noted that, "In addition to our more advanced technology, we are distinguished by our specific expertise in flow cytometry. Unlike many of the larger companies, which may have projects and programs going on across the whole spectrum of science, Cytek is solely focused on flow cytometry. This means that we don't get distracted from our mission – making high-end, high-quality flow cytometry accessible to a larger number of researchers."

Looking forward, Cytek – which already has a presence in the U.S. and China – intends to expand into Europe by the end of the year. The company will also introduce a new, value flow cytometry solution dubbed Cytek Northern Lights. This new offering will incorporate the same spectral technology as the Cytek Aurora and enable the company to put the power, flexibility and intuitiveness of its flow cytometry solutions into the hands of even more scientists.